Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: bendamustine
Drug: Fludarabine

First Posted Date: 2011-08-25

Last Posted Date: 2011-08-25

Lead Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH

Target Recruit Count: 96

Registration Number: NCT01423032

Locations: 🇩🇪
Prof. Dr. Norbert Niederle, Leverkusen, NRW, Germany

Reduced Intensity Double Umbilical Cord Blood Transplantation

Phase 2

Completed

Conditions: Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Multiple Myeloma
Acute Myelogenous Leukemia

Interventions: Drug: Fludarabine
Drug: Melphalan
Radiation: Total Body Radiation
Biological: Cord Blood

First Posted Date: 2011-08-03

Last Posted Date: 2019-01-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT01408563

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Interleukin-2
Drug: Anti-Thymocyte Globulin
Procedure: Allogeneic related Stem Cell Transplant
Drug: Tacrolimus
Drug: Methotrexate
Drug: G-CSF

First Posted Date: 2011-07-11

Last Posted Date: 2016-02-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01390402

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Acute Lymphoblastic Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
Chronic Eosinophilic Leukemia
Chronic Myelomonocytic Leukemia
Chronic Neutrophilic Leukemia
Essential Thrombocythemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Interventions: Drug: Fludarabine
Drug: Busulfan
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide (CY)
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Device: Allogeneic hematopoietic stem cell transplantation
Procedure: Peripheral blood stem cell transplantation (PBSCT)

First Posted Date: 2011-06-29

Last Posted Date: 2022-11-17

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 40

Registration Number: NCT01384513

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia CLL

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2011-06-10

Last Posted Date: 2016-03-16

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 140

Registration Number: NCT01370772

Locations: 🇫🇷
Stephane LEPRETRE, Rouen, CLCC Henri Becquerel, France
🇫🇷
Guillaume CARTRON, Montpellier, Regional university Hospital, France

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Aldesleukin
Biological: Tumor Infiltrating Lymphocytes

First Posted Date: 2011-06-09

Last Posted Date: 2019-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01369875

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Phase 1

Terminated

Conditions: Skin Cancer
Metastatic Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor Infiltrating Lymphocytes
Drug: IL-15

First Posted Date: 2011-06-09

Last Posted Date: 2015-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT01369888

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cord Blood Transplantation for Patients With Cancer

Phase 2

Terminated

Conditions: Hematological Disease

Interventions: Drug: Melphalan
Drug: Antithymocyte Globulin (ATG)
Drug: Fludarabine
Drug: Busulfan
Drug: Total Body Irradiation (TBI)

First Posted Date: 2011-05-24

Last Posted Date: 2015-04-30

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT01359254

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Phase 1

Terminated

Conditions: Acute Leukemia
Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes
Non-Hodgkin's Lymphoma
Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Myeloma
Hematologic Malignancies
Hodgkin's Lymphoma

Interventions: Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Melphalan
Device: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 8

Registration Number: NCT01350258

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Not Applicable

Terminated

Conditions: Sickle Cell Anemia
Sickle Cell-hemoglobin C Disease
Sickle Cell-β0-thalassemia

Interventions: Drug: Fludarabine
Drug: Cytarabine
Device: Cellular Infusions
Radiation: Total Body Irradiation
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Rituximab
Procedure: Plasmapheresis

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 2

Registration Number: NCT01350232

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy